Tech Company Financing Transactions
Syntimmune Funding Round
Syntimmune secured a $1 million funding round on 3/23/2016. Backers included Apple Tree Partners, Baxalta Ventures and Partners Innovation Fund.
Transaction Overview
Company Name
Announced On
3/23/2016
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
116 Huntington Ave. 301
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Founded in 2013, Syntimmune is the world's leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean Kress
Chief Financial Officer
John McBride
Chief Medical Officer
Mario Saltarelli
Vice President
Stephanie Haller
Vice President
Nicole Luosey
VP - Operations
Adam Hansard
VP - Regulatory Affairs
Donald Johns
VP - Regulatory Affairs
Leslie Stolz
Browse more venture capital transactions:
Prev: 3/23/2016: Zodiac venture capital transaction
Next: 3/23/2016: Medical Departures venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs